154 related articles for article (PubMed ID: 9477128)
1. High dose cytosine arabinoside is a major risk factor for the development of hepatosplenic candidiasis in patients with leukemia.
Woolley I; Curtis D; Szer J; Fairley C; Vujovic O; Ugoni A; Spelman D
Leuk Lymphoma; 1997 Nov; 27(5-6):469-74. PubMed ID: 9477128
[TBL] [Abstract][Full Text] [Related]
2. Analysis of factors related to the occurrence of chronic disseminated candidiasis in patients with acute leukemia in a non-bone marrow transplant setting: a follow-up study.
Sallah S; Wan JY; Nguyen NP; Vos P; Sigounas G
Cancer; 2001 Sep; 92(6):1349-53. PubMed ID: 11745210
[TBL] [Abstract][Full Text] [Related]
3. Low dose cytosine arabinoside in the treatment of acute non-lymphoblastic leukemia.
Insiripong S; Thaisamakr S
J Med Assoc Thai; 1996 Sep; 79(9):568-71. PubMed ID: 8996985
[TBL] [Abstract][Full Text] [Related]
4. Anterior uveitis associated with high-dose cytosine arabinoside.
Fintelmann RE; Qian Y; Skalet A; Jeng BH
Ocul Immunol Inflamm; 2010 Dec; 18(6):485-7. PubMed ID: 20887203
[TBL] [Abstract][Full Text] [Related]
5. High Dose Cytosine Arabinoside in the consolidation of adult acute myeloid leukemia.
Rahman MH; Khan MA; Islam MS; Afrose S; Ara T
Mymensingh Med J; 2012 Apr; 21(2):213-9. PubMed ID: 22561761
[TBL] [Abstract][Full Text] [Related]
6. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor.
Bradley AM; Deal AM; Buie LW; van Deventer H
Pharmacotherapy; 2012 Dec; 32(12):1070-7. PubMed ID: 23208834
[TBL] [Abstract][Full Text] [Related]
7. Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside.
Ozkan A; Apak H; Celkan T; Yüksel L; Yildiz I
Pediatr Dermatol; 2001; 18(1):38-40. PubMed ID: 11207969
[TBL] [Abstract][Full Text] [Related]
8. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
Zeremski V; Savić A
Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
[TBL] [Abstract][Full Text] [Related]
9. Flushing out of cerebrospinal fluid as a therapy for acute cerebellar dysfunction caused by high dose of cytosine arabinoside: a case report.
Pellier I; Leboucher B; Rachieru P; Ifrah N; Rialland X
J Pediatr Hematol Oncol; 2006 Dec; 28(12):837-9. PubMed ID: 17164656
[TBL] [Abstract][Full Text] [Related]
10. Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.
Bainschab A; Quehenberger F; Greinix HT; Krause R; Wölfler A; Sill H; Zebisch A
Leuk Res; 2016 Mar; 42():47-51. PubMed ID: 26866663
[TBL] [Abstract][Full Text] [Related]
11. "Flushing out" cytosine arabinoside from CSF to reverse neurotoxicity.
Bleyer A
J Pediatr Hematol Oncol; 2007 Apr; 29(4):274. PubMed ID: 17414574
[No Abstract] [Full Text] [Related]
12. Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.
Amaki J; Onizuka M; Ohmachi K; Aoyama Y; Hara R; Ichiki A; Kawai H; Sato A; Miyamoto M; Toyosaki M; Machida S; Kojima M; Shirasugi Y; Kawada H; Ogawa Y; Ando K
Int J Hematol; 2015 Jun; 101(6):543-53. PubMed ID: 25735499
[TBL] [Abstract][Full Text] [Related]
13. Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman.
Friedman JH; Shetty N
Mov Disord; 2001 May; 16(3):575-7. PubMed ID: 11391764
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival following radiotherapy and cytarabine chemotherapy for sporadic primary central nervous system lymphoma.
Pöttgen C; Stuschke M; Stüben G; Schmitz A; Schwechheimer K; Wacker HH; Rauhut F; Kleuker S; Wilhelm H; Grehl S; Fehlings T
Strahlenther Onkol; 2003 Sep; 179(9):626-32. PubMed ID: 14628129
[TBL] [Abstract][Full Text] [Related]
16. Cytosine arabinoside-induced vasculitis.
Ahmed I; Chen KR; Nakayama H; Gibson LE
Mayo Clin Proc; 1998 Mar; 73(3):239-42. PubMed ID: 9511781
[TBL] [Abstract][Full Text] [Related]
17. Severe anterior uveitis as a complication of high-dose cytosine-arabinoside.
Moberg J; Carlsson M; Holm C; Koranyi G
Acta Ophthalmol; 2009 Nov; 87(8):922-3. PubMed ID: 19799589
[No Abstract] [Full Text] [Related]
18. [Hepatosplenic candidiasis in acute myeloid leukemia].
Larregina A; Bartoletti B; Romano H; Paniccia L; Polini NN
Rev Argent Microbiol; 2004; 36(1):28-30. PubMed ID: 15176375
[TBL] [Abstract][Full Text] [Related]
19. [Hepatosplenic candidiasis in acute leukaemia patients].
Rajić Z; Colović N; Sretenović M; Plecić M; Janković S; Bakrac M; Colović M
Srp Arh Celok Lek; 2008; 136(7-8):414-8. PubMed ID: 18959179
[TBL] [Abstract][Full Text] [Related]
20. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
